What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His scientific interests lie mostly in Internal medicine, Cancer, Oncology, Cancer research and Pathology.
His research integrates issues of Mutation, Immunology, Genetic testing and Drug resistance in his study of Cancer.
His Oncology research includes themes of Chemotherapy, Genome, Targeted therapy, Carcinoma and Prospective cohort study.
His work carried out in the field of Targeted therapy brings together such families of science as Precision medicine, DNA sequencing and Genomics.
The concepts of his Cancer research study are interwoven with issues in Entrectinib, Trk receptor, Mutant, AKT1 and KRAS.
His Clinical trial study incorporates themes from Young adult and Overall response rate.
His most cited work include:
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients (1320 citations)
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations (972 citations)
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children (852 citations)
What are the main themes of his work throughout his whole career to date?
David M. Hyman mainly focuses on Internal medicine, Oncology, Cancer, Cancer research and Clinical trial.
His study in the field of Adverse effect, Cohort, Clinical endpoint and Ovarian cancer is also linked to topics like In patient.
His study looks at the intersection of Oncology and topics like Germline with Germline mutation.
He has researched Cancer in several fields, including Mutation and Bioinformatics.
David M. Hyman usually deals with Cancer research and limits it to topics linked to Trk receptor and Protein kinase domain.
David M. Hyman studies Pathology, namely Histiocytosis.
He most often published in these fields:
- Internal medicine (67.05%)
- Oncology (56.68%)
- Cancer (40.55%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (67.05%)
- Oncology (56.68%)
- Cancer (40.55%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Oncology, Cancer, Cancer research and Clinical trial.
The Internal medicine study combines topics in areas such as Gastroenterology and PTEN.
The study incorporates disciplines such as INVESTIGATIONAL AGENTS, Precision medicine, Metastatic breast cancer and Cohort in addition to Oncology.
His Cancer research is multidisciplinary, incorporating elements of Mutation, Salivary gland, Discontinuation and Confidence interval.
His Cancer research research is multidisciplinary, incorporating perspectives in Trastuzumab, Mutant, Gene, Fibroblast growth factor receptor and Kinase.
His Clinical trial study combines topics in areas such as Incidence, Drug development, Quality of life, Leiomyosarcoma and ATRX.
Between 2019 and 2021, his most popular works were:
- NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls (111 citations)
- NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls (111 citations)
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. (101 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
David M. Hyman spends much of his time researching Cancer research, Cancer, Internal medicine, Lineage and Trk receptor.
His studies deal with areas such as Trastuzumab, Lung cancer, Pathology, Gene and Cytotoxic T cell as well as Cancer research.
His Cancer research includes elements of CHEK2 and Glioma.
His Internal medicine research integrates issues from PI3K/AKT/mTOR pathway, PTEN and Oncology.
His Oncology study combines topics from a wide range of disciplines, such as Cancer screening, Cohort, Medical diagnosis, Point of care and DNA sequencing.
His Trk receptor research incorporates themes from Absolute neutrophil count, Young adult, Adverse effect, Genome and Clinical endpoint.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
